Correction to: Neuropsychopharmacology advance online publication, 2 March 2016; doi:10.1038/npp.2016.18
Following the publication of this paper, the authors have changed the Funding and Disclosure section to read as follows:
This work was funded by the Wellcome trust (103838), Parkinson’s UK, National Institute for Health Research’s Cambridge Biomedical Research Centre and the Medical Research Council (MC_US_A060_0016 and RG62761), and the James F McDonnell Foundation (21st century science initiative on Understanding Human Cognition). The BCNI is supported by a joint award from the Wellcome Trust and Medical Research Council.
TWR reported receiving grants from GlaxoSmithKline, Lilly and Lundbeck; consulting fees from Merck, GlaxoSmithKline, Lundbeck, Lilly, Teva, Shire, Otsuka, and Cambridge cognition; honorarium from Springer-Verlag for Psychopharmacology editorial duties; and payments from Cambridge Cognition for Cambridge Neuropsychological Test Automated Battery (CANTAB). The authors declare no conflict of interest.
Additional information
The online version of the original article can be found at 10.1038/npp.2016.18
Rights and permissions
About this article
Cite this article
Borchert, R., Rittman, T., Passamonti, L. et al. Erratum: Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease. Neuropsychopharmacol 41, 2188 (2016). https://doi.org/10.1038/npp.2016.46
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2016.46
This article is cited by
-
Neuromodulation of prefrontal cortex cognitive function in primates: the powerful roles of monoamines and acetylcholine
Neuropsychopharmacology (2022)
-
Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus
Psychopharmacology (2022)